The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
HIGH INCIDENCE OF RECEPTORS FOR LUTEINIZING HORMONE-RELEASING HORMONE (LHRH) AND LHRH RECEPTOR GENE EXPRESSION IN HUMAN PROSTATE CANCERS
Open accessAbstract
PURPOSE: Agonistic analogs of luteinizing hormone-releasing hormone (LHRH) are widely used for therapy of advanced prostate cancer based upon their ability to suppress testosterone secretion in patients. Various studies also indicate that LHRH analogs might have direct inhibitory effects on prostate tumors mediated by specific LHRH receptors. In this study we investigated the presence and characteristics of receptors for LHRH and their messenger (m) ribonucleic acid (RNA) expression in specimens of human prostate adenocarcinomas and benign prostatic tissue. MATERIALS AND METHODS: In vitro ligand competition assays as well as reverse transcriptase polymerase chain reaction (RT-PCR) were performed to investigate the expression of receptors for LHRH in surgical specimens of human prostate cancers and benign prostatic tissue. RESULTS: Sixty-nine of 80 (86%) cancers exhibited specific, medium to high-affinity binding for [D-Trp6]LHRH with a dissociation constant (Kd) of 6.55+/-0.4 nM and a maximal binding capacity (Bmax) of 483.6+/-25.4 fmol./mg. membrane protein. Two prostate cancer patients who were treated with the LHRH agonist goserelin prior to prostatectomy did not show tumor LHRH receptors. The expression of mRNA for LHRH receptors was observed in 19 of 22 (86%) prostate cancers. Benign prostatic tissue also displayed LHRH receptor gene expression, but exhibited lower Bmax value. There was a negative correlation (p <0.001) between LHRH receptor binding capacity and cancer grade (Gleason score); higher Gleason scores were associated with significantly lower binding capacity but an increased binding affinity. CONCLUSIONS: The expression of specific receptor proteins for LHRH in human prostate cancer provides a rationale for the improvement in methods for therapy of this malignancy based on LHRH analogs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma
Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A., & Goodman, P. J. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908173210702 · Cited by 1,464
Cited by
Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy
Reubi, J. C. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0007 · Cited by 1,131
Molecular Biology of Gonadotropin-Releasing Hormone (GnRH)-I, GnRH-II, and Their Receptors in Humans
Cheng, C. K., & Leung, P. C. K. (2005) · Endocrine Reviews · doi:10.1210/er.2003-0039 · Cited by 302
Recent developments in anticancer drug delivery using cell penetrating and tumor targeting peptides
Dissanayake, S., Denny, W. A., Gamage, S., & Sarojini, V. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.02.006 · Cited by 280
Hypothalamic Hormones and Cancer
Schally, A. V., Comaru-Schally, A. M., Nagy, A., Kovacs, M., Szepeshazi, K., Plonowski, A., Varga, J. L., & Halmos, G. (2001) · Frontiers in Neuroendocrinology · doi:10.1006/frne.2001.0217 · Cited by 254
Self-citation
Metadata
- Authors
- HALMOS, G., ARENCIBIA, J. M., SCHALLY, A. V., DAVIS, R., & BOSTWICK, D. G.
- Venue
- Journal of Urology
- Published
- 2000-02
- Volume
- 163
- Issue
- 2
- Pages
- 623-629
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2167733127
- Cited by
- 163
- References
- 1
- FWCI
- 8.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HIGH INCIDENCE OF RECEPTORS FOR LUTEINIZING HORMONE-RELEASING HORMONE (LHRH) AND LHRH RECEPTOR GENE EXPRESSION IN HUMAN PROSTATE CANCERS. https://app.cochat.ai/papers/10.1016/s0022-5347(05)67947-5
- The paper
- HALMOS, G., ARENCIBIA, J. M., SCHALLY, A. V., DAVIS, R., & BOSTWICK, D. G. (2000). HIGH INCIDENCE OF RECEPTORS FOR LUTEINIZING HORMONE-RELEASING HORMONE (LHRH) AND LHRH RECEPTOR GENE EXPRESSION IN HUMAN PROSTATE CANCERS. Journal of Urology. https://doi.org/10.1016/s0022-5347(05)67947-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.